Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Peter W CollinsD V K QuonMichael P MakrisPratima ChowdaryC L KemptonS J ApteM V RamananCharles R M HayB DrobicY HuaT J BabinchakE D GompertsPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)
IB1001 is safe and efficacious for treatment of bleeds, routine prophylaxis and perioperative management in haemophilia B patients.